Changes of Serum Lipid Concentration and Serum Liver Enzyme Levels During Etretinate Treatment in Patients with Psoriasis.
- Author:
Jun Gyu OH
;
Dae Hun SUH
;
Jai Il YOUN
- Publication Type:Original Article
- Keywords:
Etretinate;
Serum lipid;
Serum liver enzyme;
Psoriasis
- MeSH:
Acitretin*;
Alanine Transaminase;
Aspartate Aminotransferases;
Atherosclerosis;
Cholesterol;
Etretinate*;
Hepatitis B Surface Antigens;
Humans;
Hypertension;
Korea;
Liver Diseases;
Liver*;
Prevalence;
Psoriasis*;
Risk Factors;
Triglycerides
- From:Korean Journal of Dermatology
1995;33(4):641-649
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Oral etretinate treatment is associated with the changes in serum lipid concentration and the elevation of serum liver enzymes. In Korea, chronic degenerative diseases like diabetes and hypertension are increasing and the prevalences of HBsAg and chronic liver diseases are much higher than those in western countries. Therefore these changes in serum lipids and liver enzymes during etretinate treatrment are important in Korea as risk factors for atherosclerosis and aggravation of preexisting liver diseases. OBJECTIVE: We tried to observe the sequential pattern, frequency, severity, and relationship between pretreatment value and posttreatment values in the changes of serum lipids and liver enzymes in patients with psoriasis luring etretinate treatment. METHODS: Fourty-one patients with psoriasis were studied during etretinate treatment with the starting dose of 0.5-1.0mg/kg/day. The levels of serum triglyceride, serum cholesterol, HDL-cholesterol, and sGOT, sGPT was repeatedly determined until the 16th week of etretinate treatment. RESULTS: l. In serum triglyceride and cholesterol, the average of concentrations in each treatment period was usually higher than pretreatment value during the 16 weeks of treatment, but no sequential pattern of changes was observed 2. The number of patients with the maximum of posttreatment values higher than the normal limit were 12(29.3%) in triglyce side, 6(14.6%) in cholesterol, 0 in sGOT, and 5(12.5%) in sGPT. The number of patients with the minimum of posttreatment values lower than the normal limit were 15(36.6%) in HDL-cholesterol. 3. In serum cholesterol, patients with an abnormal pretreatment value are more prone to elevation above the normal limit duriing etretinate treatment than patients with a normal pretreatment value. CONCLUSION: In patients with psoriasis the increases in serum triglyceride, serum cholesterol, sGOT, sGPT and the decrease in HDL-cholesterol were occurred frequently during etretinate treatment. Therefore monitoring of serum lipid concentration and serum liver enzyme levels on a regular basis during etretinate treatment is essential for its safe use in patients with psoriasis, es- pecially in cases of long term etretinate treatment.
